Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Common Equity (2016 - 2017)

Bone Biologics has reported Common Equity over the past 3 years, most recently at -$8.4 million for Q4 2017.

  • Quarterly Common Equity changed 0.38% to -$8.4 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was -$8.4 million through Dec 2017, changed 0.38% year-over-year, with the annual reading at -$8.4 million for FY2017, 0.38% changed from the prior year.
  • Common Equity was -$8.4 million for Q4 2017 at Bone Biologics, up from -$10.2 million in the prior quarter.
  • Over five years, Common Equity peaked at -$3.2 million in Q1 2016 and troughed at -$10.2 million in Q3 2017.
  • The 3-year median for Common Equity is -$7.8 million (2017), against an average of -$7.1 million.
  • The largest YoY upside for Common Equity was 0.38% in 2017 against a maximum downside of 143.29% in 2017.
  • A 3-year view of Common Equity shows it stood at -$4.2 million in 2015, then crashed by 99.23% to -$8.4 million in 2016, then decreased by 0.38% to -$8.4 million in 2017.
  • Per Business Quant, the three most recent readings for BBLG's Common Equity are -$8.4 million (Q4 2017), -$10.2 million (Q3 2017), and -$9.7 million (Q2 2017).